• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MicroRNA-451a downregulation in liraglutide-treated individuals with diabetes: A potential cardiovascular protective mechanism.

作者信息

Kongrat Surachai, Sungkaworn Titiwat, Muanprasat Chatchai, Sriphrapradang Chutintorn, Yingchoncharoen Teerapat

机构信息

Division of Cardiology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Faculty of Medicine Ramathibodi Hospital, Chakri Naruebordindra Medical Institute, Mahidol University, Bang Phli, Thailand.

出版信息

Diab Vasc Dis Res. 2024 Sep-Oct;21(5):14791641241278527. doi: 10.1177/14791641241278527.

DOI:10.1177/14791641241278527
PMID:39325062
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11437537/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/047a/11437537/a3d4d75130e4/10.1177_14791641241278527-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/047a/11437537/a3d4d75130e4/10.1177_14791641241278527-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/047a/11437537/a3d4d75130e4/10.1177_14791641241278527-fig1.jpg

相似文献

1
MicroRNA-451a downregulation in liraglutide-treated individuals with diabetes: A potential cardiovascular protective mechanism.利拉鲁肽治疗的糖尿病患者中MicroRNA-451a表达下调：一种潜在的心血管保护机制。
Diab Vasc Dis Res. 2024 Sep-Oct;21(5):14791641241278527. doi: 10.1177/14791641241278527.
2
Insulin degludec/liraglutide (Xultophy 100/3.6) for type 2 diabetes.德谷胰岛素/利拉鲁肽（Xultophy 100/3.6）用于2型糖尿病。
Med Lett Drugs Ther. 2017 Sep 11;59(1529):147-149.
3
London buses: A cardiovascular outcome trial equivalent?伦敦巴士：等同于心血管结局试验？
Diab Vasc Dis Res. 2016 Nov;13(6):382-383. doi: 10.1177/1479164116663051. Epub 2016 Aug 18.
4
Effect of Liraglutide on Arterial Inflammation Assessed as [F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.利拉鲁肽对 2 型糖尿病患者动脉炎症的影响：一项随机、双盲、安慰剂对照试验。
Circ Cardiovasc Imaging. 2021 Jul;14(7):e012174. doi: 10.1161/CIRCIMAGING.120.012174. Epub 2021 Jun 30.
5
Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.利拉鲁肽可降低新诊断的超重 2 型糖尿病合并非酒精性脂肪性肝病患者的肝脏脂肪含量和血清成纤维细胞生长因子 21 水平。
J Diabetes Res. 2021 Oct 8;2021:3715026. doi: 10.1155/2021/3715026. eCollection 2021.
6
Liraglutide effects on epicardial adipose tissue micro-RNAs and intra-operative glucose control.利拉鲁肽对心外膜脂肪组织微小RNA及术中血糖控制的影响
Nutr Metab Cardiovasc Dis. 2025 Feb;35(2):103726. doi: 10.1016/j.numecd.2024.08.019. Epub 2024 Aug 30.
7
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.利拉鲁肽治疗 2 型糖尿病合并慢性肾脏病的安全性。
Clin J Am Soc Nephrol. 2020 Apr 7;15(4):465-473. doi: 10.2215/CJN.11881019. Epub 2020 Mar 4.
8
The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes.利拉鲁肽对 2 型糖尿病患者心外膜脂肪组织的影响。
J Diabetes Res. 2021 Nov 16;2021:5578216. doi: 10.1155/2021/5578216. eCollection 2021.
9
Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.利拉鲁肽对比度拉鲁肽在日本 2 型糖尿病患者中的真实世界疗效：一项回顾性研究。
Sci Rep. 2022 Jan 7;12(1):154. doi: 10.1038/s41598-021-04149-z.
10
A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients.一项评估利拉鲁肽对南亚 2 型糖尿病患者异位脂肪积累影响的双盲、安慰剂对照、随机临床试验。
Cardiovasc Diabetol. 2019 Jul 9;18(1):87. doi: 10.1186/s12933-019-0890-5.

本文引用的文献

1
Vitamin C supplementation reduces expression of circulating miR-451a in subjects with poorly controlled type 2 diabetes mellitus and high oxidative stress.补充维生素C可降低2型糖尿病控制不佳且氧化应激水平高的受试者循环中miR-451a的表达。
PeerJ. 2021 Feb 4;9:e10776. doi: 10.7717/peerj.10776. eCollection 2021.
2
Liraglutide improves atherosclerosis by regulating long non-coding RNA RMRP/miR-128-1-5P/Gadd45g axis.利拉鲁肽通过调控长链非编码 RNA RMRP/miR-128-1-5P/Gadd45g 轴改善动脉粥样硬化。
Eur Rev Med Pharmacol Sci. 2020 Mar;24(5):2725-2737. doi: 10.26355/eurrev_202003_20545.
3
Incretins and microRNAs: Interactions and physiological relevance.
肠降血糖素和 microRNAs：相互作用和生理相关性。
Pharmacol Res. 2020 Mar;153:104662. doi: 10.1016/j.phrs.2020.104662. Epub 2020 Jan 23.
4
A glucagon-like peptide-1 analog, liraglutide, ameliorates endothelial dysfunction through miRNAs to inhibit apoptosis in rats.一种胰高血糖素样肽-1类似物，利拉鲁肽，通过微小RNA改善内皮功能障碍以抑制大鼠细胞凋亡。
PeerJ. 2019 Mar 6;7:e6567. doi: 10.7717/peerj.6567. eCollection 2019.
5
RNA Therapeutics in Cardiovascular Disease.心血管疾病的 RNA 治疗学
Circ Res. 2018 Jul 6;123(2):205-220. doi: 10.1161/CIRCRESAHA.117.311311.
6
Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.非编码 RNA 在心血管疾病中的作用：诊断与治疗前景。
Eur Heart J. 2018 Aug 1;39(29):2704-2716. doi: 10.1093/eurheartj/ehx165.
7
microRNA-33 Regulates Macrophage Autophagy in Atherosclerosis.微小RNA-33在动脉粥样硬化中调节巨噬细胞自噬
Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1058-1067. doi: 10.1161/ATVBAHA.116.308916. Epub 2017 Apr 20.
8
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
9
Overview of microRNA biology.微小RNA生物学概述
Semin Liver Dis. 2015 Feb;35(1):3-11. doi: 10.1055/s-0034-1397344. Epub 2015 Jan 29.
10
MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway.microRNA-451 通过抑制 LKB1/AMPK 通路加剧心肌细胞的脂毒性和高脂饮食诱导的心肌肥厚。
Circ Res. 2015 Jan 16;116(2):279-88. doi: 10.1161/CIRCRESAHA.116.304707. Epub 2014 Oct 31.